Genentech’s Tecentriq Continues to Demonstrate Its Potency as a Treatment for Lung Cancer
Πολλά υποσχόμενο το νέο φάρμακο για την ψωρίαση της Bristol-Myers
Pfizer and Merck KGaA are one step closer to a brand-new market for their immuno-oncology drug Bavencio. The companies reported winning data in a kidney cancer trial, setting them up … Continue Reading Can Pfizer and Merck KGaA parlay Bavencio combo data into a kidney cancer win?
Merck’s Keytruda threatens Pfizer, Merck KGaA’s Bavencio with Merkel cell ‘priority’ tag
Bayer and Haplogen collaborate to develop new treatments against pulmonary diseases August 14, 2018 Bayer and Haplogen GmbH, a Vienna-based biotechnology company, have entered into a multi-year research collaboration agreement … Continue Reading Top Pharma News of the Week
The U.S. Food and Drug Administration (FDA) gave Bristol-Myers Squibb’s Opdivo (nivolumab) approval for metastatic small cell lung cancer (SCLC) for patients whose cancer has progressed after platinum-based chemotherapy and at least one other type of … Continue Reading Bristol-Myers Squibb’s Opdivo Gets New Approval for Lung Cancer Indication
In the field of immuno-oncology, the two dominant players are Merck & Company, with Keytruda and Bristol-Myers Squibb Company with Opdivo. PD-1 and PD-L1 are proteins found on cancer cells that allow them … Continue Reading Merck Takes Lead from Bristol-Myers Squibb for PD-1/PD-L1
Bristol-Myers Squibb reported a strong second quarter, with total revenues of $5.7 billion, up 11 percent from the same quarter in 2017, when it reported $5.144 billion. Sales were driven by … Continue Reading Bristol-Myers Squibb Reports 11% Increase in Total Revenues for Q2
Merck’s Keytruda may just be on its way to earlier use in head and neck cancer, an area where it once faced some questions. On Wednesday, the New Jersey drugmaker said that … Continue Reading Merck’s Keytruda shores up head and neck case with first-line trial win
Bristol-Myers Squibb is locked in some pretty big marketing battles—but it’ll have to soldier on without its commercial leader. On Monday, the New Jersey drugmaker said EVP and chief commercial officer … Continue Reading Bristol-Myers Squibb commercial chief Gordon jumps ship ahead of key Opdivo launch
Roche’s Tecentriq is on a much-needed hot streak. On Tuesday, the immuno-oncology drug—in combination with Roche’s Avastin—picked up a breakthrough therapy designation from the FDA in previously untreated liver … Continue Reading Roche’s Tecentriq extends its hot streak with liver cancer combo breakthrough
Tally another win for Bristol-Myers Squibb’s immunotherapy combination. Wednesday, the New Jersey drugmaker said its Opdivo-Yervoy pairing grabbed an FDA approval in patients with rare colon cancers that have progressed despite other … Continue Reading Bristol-Myers Squibb’s Opdivo-Yervoy combo wins right to challenge Merck’s Keytruda in rare cancer
In the immuno-oncology world, all eyes have been on the market battle playing out in the lucrative lung cancer arena. But with its latest data, breast cancer leader Roche is bringing … Continue Reading Roche eyes next-generation breast cancer crown with Tecentriq’s triple-negative victory
At the American Society of Clinical Oncology (ASCO) annual meeting over the weekend, Merck’s Keytruda continued its winning streak. In data presented at the meeting, the cancer immunotherapy was shown … Continue Reading Merck’s Keytruda continues its string of blockbuster results, but BMS’ Opdivo still leads in sales
CHICAGO—Bristol-Myers Squibb’s new strategy In lung cancer relies on showing its new biomarker can help predict who benefits most from immunotherapy combinations. And Monday at the American Society of Clinical Oncology annual … Continue Reading ASCO: Bristol-Myers racks up Opdivo combo data to sell its new biomarker, but will doctors buy it?
Oncology DTC advertising has soared in recent years, thanks to new drugs and mechanisms of action. (Syneos Health) As more oncology treatments have flooded the market, so has cancer DTC … Continue Reading New drugs, new money: Surge in cancer DTC ads follows wave of I-O debuts